-
Aggressive prostate cancer is surging in California. What you need to know
06 Feb 2025 22:21 GMT
Keep up with LAist.
If you're enjoying this article, you'll love our daily newsletter, The LA Report. Each weekday, catch up on the 5 most pressing stories to start your morning in 3 minutes or less.
Advanced prostate cancer cases are rising …
-
Medical news in brief: Sickle cell treatment, prostate cancer, patient complaints, and other stories
06 Feb 2025 22:19 GMT
Sickle cell disease gene editing therapy is approved
In final draft guidance the National Institute for Health and Care Excellence has approved a one-off gene editing therapy to treat severe sickle cell disease (SCD) in people aged 12 and over. Data …
-
Investornewsbreaks Kairos Pharma Ltd. (NYSE American: KAPA) Highlights Preclinical Data On GITR Agonist KROS 101 At AACR-JCA Conference
06 Feb 2025 19:57 GMT
… Investor Brand Network)
Kairos Pharma (NYSE American: KAPA) … responses and improve cancer treatment, supporting further clinical … biology to overcome drug resistance and immune suppression … 2 clinical trial for castrate resistant prostate cancer and a …
-
Refining partial gland ablation for localised prostate cancer: the FALCON project.
06 Feb 2025 12:59 GMT
To provide a contemporary statement on focal therapy (FT) for localised prostate cancer (PCa) from an international and diverse group of physicians treating localised PCa, with the aim of overcoming the limitations of previous consensus statements, which …
-
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in ESSA Pharma Inc. Lawsuit – EPIX
06 Feb 2025 18:45 GMT
… notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). … #47;securities/essa-pharma-inc-loss-submission-form… combination therapy for the treatment of prostate cancer, was unlikely to meet … #47;securities/essa-pharma-inc-loss-submission-form…
-
Cortechs.ai and EDAP Announce World’s First OnQ™ Prostate-Assisted Focal One® Robotic HIFU Procedure at UCSF Prostate Cancer Center
06 Feb 2025 13:00 GMT
… focal therapy. As the only FDA-cleared solution for RSI-MRI … patient-specific treatment to their prostate cancer patients.” Focal therapy for prostate cancer is an … and treatment planning. As focal therapy becomes increasingly integrated into prostate cancer …
-
FDA Grants Key Oncology Approvals and Designations in January 2025
06 Feb 2025 14:03 GMT
… 2 Trial
On January 10, 2025, the FDA cleared the investigational new drug … 3-Month Leuprolide Mesylate for Prostate Cancer Treatment
The FDA issued a Day-74 … Carcinoma Trial
On January 14, 2025, the FDA cleared its investigational new drug …
-
Erleada Combo Shows Comparable Quality of Life Outcomes in Prostate Cancer
06 Feb 2025 03:16 GMT
… life was maintained during the treatment period, with no statistically significant … disease with potentially life-long treatments that induce testosterone suppression and … for Advanced Prostate Cancer: Secondary Analysis of a Randomized Clinical Trial” by Dr …
-
Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma
06 Feb 2025 13:53 GMT
… structural biology to overcome drug resistance and immune suppression … resistance to various cancer treatments. Elevation of CD105 in … Phase 2 clinical trial for castrate-resistant prostate cancer and a … and projections of Kairos Pharma. We base these forward …
-
J&J’s fashion-forward fight against prostate cancer
05 Feb 2025 22:27 GMT
… amp;J is developing drugs targeting the disease, … drug discovery and R&D efforts, the pharma … degendered and transgender inclusive prostate cancer study protocols.
The … have uncomfortable conversations about prostate cancer with their healthcare providers …
About
© 1995-2025